SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia

References

• Chen W, Wang Y, Zhao A, et al. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer Cell. 2016;30:779–791.
   PubMed Web of Science ®Google Scholar
• Naoe T, Kiyoi H. Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol. 2013;97:165–174.
   PubMed Web of Science ®Google Scholar
• Prada-Arismendy J, Arroyave JC, Rothlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31:63–76.
   PubMed Web of Science ®Google Scholar
• O'Donnell MR, Abboud CN, Altman J, et al. NCCN clinical practice guidelines acute myeloid leukemia. J Natl Compr Canc Netw. 2012;10:984–1021.
   PubMed Web of Science ®Google Scholar
• Orozco JJ, Appelbaum FR. Unfavorable, complex, and monosomal karyotypes: the most challenging forms of acute myeloid leukemia. Oncology (Williston Park). 2012;26:706–712.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Wawrzyniak E, Siemieniuk-Rys M, et al. Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype – retrospective analysis of Polish Adult Leukemia Group (PALG). Leuk Lymphoma. 2017;58:889–897.
   PubMed Web of Science ®Google Scholar
• Kadia TM, Jain P, Ravandi F, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122:3484–3491.
   PubMed Web of Science ®Google Scholar
• Yohe S. Molecular genetic markers in acute myeloid leukemia. J Clin Med. 2015;4:460–478.
   PubMed Web of Science ®Google Scholar
• Gou H, Zhou J, Ye Y, et al. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China. Tumour Biol. 2016;37:7357–7370.
   PubMed Web of Science ®Google Scholar
• Pastore F, Dufour A, Benthaus T, et al. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. JCO. 2014;32:1586–1594.
   PubMed Web of Science ®Google Scholar
• Qu S, Liu B, Guo X, et al. Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD-negative acute myeloid leukemia. Cancer. 2014;120:2130–2141.
   PubMed Web of Science ®Google Scholar
• Wang H, Liu B, Al-Aidaroos AQO, et al. Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans. Oncogene. 2015;35:3303–3313.
   PubMed Web of Science ®Google Scholar
• Mazzocco M, Maffei M, Egeo A, et al. The identification of a novel human homologue of the SH3 binding glutamic acid-rich (SH3BGR) gene establishes a new family of highly conserved small proteins related to thioredoxin superfamily. Gene. 2002;291:233–239.
   PubMed Web of Science ®Google Scholar
• Tong F, Zhang M, Guo X, et al. Expression patterns of SH3BGR family members in zebrafish development. Dev Genes Evol. 2016;226:287–295.
   PubMed Web of Science ®Google Scholar
• Xu C, Zheng P, Shen S, et al. NMR structure and regulated expression in APL cell of human SH3BGRL3. Febs Lett. 2005;579:2788–2794.
   PubMed Web of Science ®Google Scholar
• Warder SE, Tucker LA, McLoughlin SM, et al. Discovery, identification, and characterization of candidate pharmacodynamic markers of methionine aminopeptidase-2 inhibition. J Proteome Res. 2008;7:4807–4820.
   PubMed Web of Science ®Google Scholar
• Egeo A, Mazzocco M, Arrigo P, et al. Identification and characterization of a new human gene encoding a small protein with high homology to the proline-rich region of the SH3BGR gene. Biochem Biophys Res Commun. 1998;247:302–306.
   PubMed Web of Science ®Google Scholar
• Egeo A, Di Lisi R, Sandri C, et al. Developmental expression of the SH3BGR gene, mapping to the down syndrome heart critical region. Mech Dev. 2000;90:313–316.
   PubMed Web of Science ®Google Scholar
• Cesareni G, Panni S, Nardelli G, et al. Can we infer peptide recognition specificity mediated by SH3 domains? Febs Lett. 2002;513:38–44.
   PubMed Web of Science ®Google Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–2221.
   PubMed Web of Science ®Google Scholar
• Park JE, Yuen HF, Zhou JB, et al. Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia. Embo Mol Med. 2013;5:1351–1366.
   PubMed Web of Science ®Google Scholar
• Slordahl TS, Abdollahi P, Vandsemb EN, et al. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells. Oncotarget. 2016;7:27295–27306.
   PubMed Web of Science ®Google Scholar
• Fagerli UM, Holt RU, Holien T, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111:806–815.
   PubMed Web of Science ®Google Scholar
• Zhou J, Cheong LL, Liu SC, et al. The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR–ABL in human chronic myeloid leukemia. Mol Cancer. 2012;11:72.
   PubMed Web of Science ®Google Scholar
• Majid SM, Liss AS, You M, et al. The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene. 2005;25:756–768.
   Web of Science ®Google Scholar
• Liang F, Liang J, Wang WQ, et al. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem. 2007;282:5413–5419.
   PubMed Web of Science ®Google Scholar
• Xiong J, Li Z, Zhang Y, et al. PRL-3 promotes the peritoneal metastasis of gastric cancer through the PI3K/Akt signaling pathway by regulating PTEN. Oncol Rep. 2016;36:1819–1828.
   PubMed Web of Science ®Google Scholar
• Thura M, Al-Aidaroos AQ, Yong WP, et al. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight. 2016;1:e87607
   PubMed Web of Science ®Google Scholar
• Green CL, Koo KK, Hills RK, et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. JCO. 2010;28:2739–2747.
   PubMed Web of Science ®Google Scholar
• Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117:2469–2475.
   PubMed Web of Science ®Google Scholar